TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Dec 06, 2012 21:00 JST
Source:
PT Bio Farma (Persero)
Melbourne University and Bio Farma to Jointly Develop Vaccine Adjuvant
Bandung, W Java, Indonesia, Dec 06, 2012 - (ACN Newswire) - Melbourne University has announced an agreement with Indonesian vaccine maker Bio Farma to develop a vaccine delivery system that can boost the vaccine effectiveness for a range of infectious diseases, including Hepatitis C, Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemopilus influenza type-B.
"Bio Farma is proud to collaborate with the University of Melbourne. This agreement will surely give us an opportunity to enhance our research capacity," said Iskandar, the President Director of Bio Farma.
Iskandar expressed hope in the future of the collaboration on a vaccine delivery system to boost vaccine effectiveness (vaccine adjuvant) which would lead into a real contribution in the prevention of communicable disease in the world.
Under the proposed arrangement, Melbourne University receives research funding to further evaluate and develop a proof of concept. The research agreement was facilitated by UoM Commercial Ltd, the University's Commercial Engagement Service company and signed on 3 September 2012.
According to Iskandar, the collaboration with Melbourne University will run for 18 months as presently the research is still in the level of proof of concept. Upon getting a result, the next step will be enhanced to a technology license level.
Professor James Angus, Dean of the Faculty of Medicine, Dentistry and Health Sciences at Melbourne University, remarked that he was delighted to be collaborating with the Board of Bio Farma and its scientific team in relation to developing a novel vaccine platform.
The vaccine platform would lead to better and more efficacious vaccines against infectious diseases. "This agreement reflects the desire for research at the University of Melbourne to be translated into impact and recognizes the importance of collaboration with leading vaccine companies to achieve this goal," said Professor Angus.
Research led by Professor David Jackson's team in the Department of Microbiology and Immunology at the University of Melbourne has shown that a synthetic TLR2 agonist-based adjuvant can enhance immunity and protect animals from viral and bacterial infections.
About the University of Melbourne
Founded in 1853, the University of Melbourne is one of Australia's oldest universities. The University is consistently ranked among the leading universities in the world and number one in Australia. In the prestigious 2012 Times Higher Education rankings of the world's top 400 universities, Melbourne ranked top in Australia and 28 in the world. For more information, please visit
http://www.unimelb.edu.au/
.
About Bio Farma
Bio Farma is Indonesia's only vaccine and antisera producer for human. Currently, the needs for Expanded Program on Immunization (EPI) vaccines in Indonesia supplied solely by Bio Farma by manufacturing and distributing over 1.7 billion doses of vaccine annually to meet the needs of EPI vaccine in the national immunization program. Bio Farma has an outstanding international reputation based on the WHO prequalification for all of its EPI vaccine products. Its products are exported to countries worldwide through direct distribution or various agencies such as UNICEF. Bio Farma has obtained the Best Export Performance from the Trade Ministry of Indonesia in the last three years up to 2012 as an evidence of its consistent exceptional performance. (T.E-004). For more information, please visit www.biofarma.co.id .
Contact:
Aat Surya Safaat
General Manager, Corporate Business Development
Perum LKBN ANTARA - Indonesian News Agency
T: +62-21-3802-2383 ext 251
M: +62-811-225-2228
E:
aat@antara.co.id
U: www.antaranews.com
Source: PT Bio Farma (Persero)
Sectors: Daily Finance, BioTech
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Related Press Release
Bio Farma secures Multi-year Purchase Contract from UNICEF for its novel Oral Polio Vaccine type 2 (nOPV2)
October 04 2022 07:00 JST
Bio Farma to Export its Polio Vaccine After Securing Purchase Contracts from UNICEF for 2022 and 2023
September 30 2022 18:00 JST
Indonesian pharmaceutical Bio Farma ready to produce IndoVac Covid-19 vaccines
September 09 2022 17:00 JST
9th International Conference on Typhoid, Invasive NTS Disease Held in Bali, Indonesia
May 01 2015 14:00 JST
Bio Farma Rolls Out Pentavalent Vaccine to All Provinces of Indonesia in 2014
December 09 2014 13:00 JST
Bio Farma Continues Presidency of the Developing Country Vaccine Manufacturers Network (DCVMN)
December 05 2014 19:00 JST
Bio Farma Awarded Gold PROPER by the Indonesian Ministry Of Environment & Forestry
December 04 2014 18:00 JST
Indonesia as the Hub of Excellence for Biological Products for Islamic Countries
October 23 2013 16:30 JST
Bio Farma Launches Pentavalent Vaccine, Combining Five Antigens
August 24 2013 12:00 JST
Bio Farma Holds Third Indonesian Vaccine Research Forum
July 02 2013 21:00 JST
More Press release >>
Latest Press Release
Mitsubishi Corporation Announces Corporate Strategy 2027
Apr 04, 2025 09:04 JST
SMBC and Fujitsu partner towards creation of AI-powered data analytics business
Apr 03, 2025 22:10 JST
Prideone Entertainment Announces New Post-War Film to Commemorate the 80th Anniversary of World War II's End
Apr 03, 2025 07:00 JST
"GTF Advantage" Engine Achieved FAA Type Certification
Apr 02, 2025 17:41 JST
Hitachi's New Corporate Vision: Changing the World and Future with the Power of Knowledge
Apr 01, 2025 18:46 JST
Hitachi: Strengthening Our Analytical Business to Solve Social Issues with Our Core Technologies
Apr 01, 2025 18:38 JST
Hitachi: Completion of New Production Facility for Semiconductor Manufacturing Equipment in Kasado Area
Apr 01, 2025 17:52 JST
NEC has developed technologies that enable a secure workflow for personalized cancer vaccines and has proven their capabilities
Apr 01, 2025 16:15 JST
Mitsubishi Motors Launches Miland Virtual Car Lifestyle App Service
Apr 01, 2025 14:59 JST
Mitsubishi Corporation: Development of R&D Hub "iPark Kobe" in Kobe Medical Industry City
Apr 01, 2025 14:16 JST
Eisai to Divest Rights for Pariet in China to Peak Pharma
Apr 01, 2025 13:15 JST
Everbright Grand China Assets Recorded Revenue of RMB 45.9 Million in 2024
Apr 01, 2025 12:25 JST
MHIEC Receives Order for Full Refurbishment of Waste Incineration Plant in Itoman City, Okinawa Prefecture
Apr 01, 2025 11:45 JST
MHI Concludes "Mizuho Eco Finance" Commitment Line Agreement
Apr 01, 2025 10:51 JST
MHI Concludes Nissay Positive Impact Finance Agreement
Apr 01, 2025 09:54 JST
Gome Retail Continues to Focus on Its Main Business and Actively Resolve Debt
Apr 01, 2025 02:36 JST
Cryofocus Medtech: Steady Increase in Revenue and Gross Profit with Solid R&D Expenditures in 2024
Apr 01, 2025 01:42 JST
Five NTT Group Companies and Biome Inc. Start Joint Development of Large-scale Estimation Technology for Vegetation and Organisms using Satellite Image Data
Mar 31, 2025 15:43 JST
TANAKA Memorial Foundation Announces Recipients of Precious Metals Research Grants
Mar 31, 2025 11:00 JST
Fujitsu and Macquarie University partner to help address critical shortage of machine learning engineers
Mar 31, 2025 09:28 JST
More Latest Release >>